Прикладная клиническая фармакокинетика - Ларри А. Бауэр

PRZEDMIOTEM OFERTY JEST KOD DOSTĘPOWY DO KSIĄŻKI ELEKTRONICZNEJ (EBOOK)

KSIĄŻKA JEST DOSTĘPNA NA ZEWNĘTRZNEJ PLATFORMIE. KSIĄŻKA NIE JEST W POSTACI PLIKU.

The most current, hands-on book in the field, Applied Clinical Pharmacokinetics The perfect textbook for pharmacy students learning the clinical application of pharmacokinetics, which is the mathematical tools for modifying doages. Students like that each chapter includes sample problems throughout the chapter, with a ton of practice problems at the end. Answers for the practice problems are in the back, but not detailed like the sample problems) *Changes in the 3/e includes: *All chapters updated and revised, as needed, including critical new references *Antibiotic individualization and monitoring sections increases use of pharmacodynamic parameters (Cmax/MIC, AUC24/MIC, Time above MIC) in addition to pharmacokinetic parameters to adjust dosages *Anticonvulsants section includes 5 new agents (Fosphenytoin, Lamotrigine, Levetiracetam, Oxcarbazepine, Eslicarbazepine) *Immunosuppressants section includes 1 new agent (Sirolimus), About the Book Text focuses on the latest standardized techniques and approaches to patient-specific dosing and provides up-to-date information on more recently moniotored drugs. Features Clear, useful coverage of drug dosing and drug monitoring Clear and concise summary of pharmacokinetic and pharmacodynamic concepts Practical help with calculations and equations Focus on the latest standardized techniques and approaches to patient-specific dosing Up-to-date information on more recently monitored drugs Essential information on drug dosing in special populations, including patients with renal and hepatic disease, obesity, and congestive heart failure All the information practitioners need on drug categories such as antibiotics, cardiovascular agents, anticonvulsants, and immunosuppressants Full coverage of drugs such as Aminoglycosides, Vancomycin, Digoxin, Phenytoin, Carbamazepine, Theophylline, Cyclosporine, Tacrolimus, and Lithium Student friendly approach to teaching pharmacokinetics--sample problems embedded into the text to allow for students to apply what they are learing. .

• Autorzy: Larry A. Bauer
• Wydawnictwo: McGraw-Hill Professional
• Data wydania: 2014
• Wydanie: 3
• Liczba stron:
• Forma publikacji: ePub (online)
• Język publikacji: angielski
• ISBN: 9780071794596

• Cover
• Title Page
• Copyright Page
• Dedication
• Contents
• About the Author
• Foreword
• From Applied Clinical Pharmacokinetics, Second Edition
• From Applied Clinical Pharmacokinetics, First Edition
• I. Basic concepts
• 1. Clinical Pharmacokinetic and Pharmacodynamic Concepts
• Introduction
• Linear Versus Nonlinear Pharmacokinetics
• Clearance
• Volume of distribution
• Half-life and Elimination Rate Constant
• Michaelis-Menten or Saturable Pharmacokinetics
• Bioavailability
• Problems
• Answers to Problems
• 2. Clinical Pharmacokinetic Equations and Calculations
• Introduction
• One-Compartment Model Equations for Linear Pharmacokinetics
• Designing Individualized Dosage Regimens Using One-Compartment Model Equations
• Multicompartment Models
• Michaelis-Menten Equations for Saturable Pharmacokinetics
• Calculation of Clearance, Volume of Distribution, and Half-life in Pharmacokinetic Research Studies
• Problems
• Answers to Problems
• 3. Drug Dosing in Special Populations: Renal and Hepatic Disease, Dialysis, Heart Failure, Obesity, and Drug Interactions
• Introduction
• Renal Disease
• Hepatic Disease
• Heart Failure
• Dialysis
• Hemodialysis
• Hemofiltration
• Peritoneal Dialysis
• Obesity
• Drug Interactions
• Problems
• Answers to Problems
• II. Antibiotics
• 4. The Aminoglycoside Antibiotics
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Aminoglycoside Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Aminoglycoside Serum Concentrations to Alter Dosages
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Special Dosing Considerations
• Problems
• Answers to Problems
• 5. Vancomycin
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Vancomycin Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Vancomycin Serum Concentrations to Alter Dosages
• Area Under the Curve Method
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• III. Cardiovascular Agents
• 6. Digoxin
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Digoxin Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Pharmacokinetic Dosing Method
• Use of Digoxin Serum Concentrations to Alter Dosages
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Special Dosing Considerations
• Problems
• Answers to Problems
• 7. Lidocaine
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Lidocaine Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Lidocaine Serum Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Use of Lidocaine Booster Doses to Immediately Increase Serum Concentrations
• Problems
• Answers to Problems
• 8. Procainamide/N-acetyl Procainamide
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Procainamide Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Procainamide and N-Acetylprocainamide Serum Concentrations to Alter Doses
• Chiou Method
• Bayesian Pharmacokinetic Computer Programs
• Use of Procainamide Booster Doses to Immediately Increase Serum Concentrations
• Dosing Strategies
• Conversion of Procainamide Doses From Intravenous to Oral Route of Administration
• Problems
• Answers to Problems
• 9. Quinidine
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Quinidine Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Quinidine Serum Concentrations to Alter Doses
• Dosing Strategies
• Conversion of Quinidine Doses From One Salt Form to Another
• Problems
• Answers to Problems
• IV. Anticonvulsants
• 10. Phenytoin/Fosphenytoin
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Usefulness of Unbound Phenytoin Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Impact of Altered Plasma Protein Binding on Phenytoin Pharmacokinetics
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Literature-Based Recommended Dosing
• Use of Phenytoin Serum Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Use of Phenytoin Booster Doses to Immediately Increase Serum Concentrations
• Problems
• Answers to Problems
• 11. Carbamazepine
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Carbamazepine Serum Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Problems
• Answers to Problems
• 12. Valproic Acid
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Valproic Acid Serum Concentrations to Alter Doses
• Pharmacokinetic Parameter Method
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• 13. Phenobarbital/Primidone
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Phenobarbital and Primidone Serum Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• 14. Ethosuximide
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Ethosuximide Serum Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• 15. Lamotrigine
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Diseases and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Lamotrigine Serum Concentrations to Alter Doses
• Selection of Appropriate Pharmacokinetic Model and Equations
• Bayesian Pharmacokinetics Computer Programs
• Special Dosing Considerations
• Problems
• Answers to Problems
• 16. Levetiracetam
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Diseases and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Levetiracetam Serum Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Special Dosing Considerations
• Problems
• Answers to Problems
• 17. Oxcarbazepine/Eslicarbazepine
• Introduction
• Oxcarbazepine
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of MHD Serum Concentrations to Alter Doses of Oxcarbazepine
• Bayesian Pharmacokinetics Computer Programs
• Eslicarbazepine
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Serum Concentrations to Alter Doses of Eslicarbazepine
• Bayesian Pharmacokinetics Computer Programs
• Problems
• Answers to Problems
• V. Immunosuppressants
• 18. Cyclosporine
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Cyclosporine Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Cyclosporine Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• 19. Tacrolimus
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Tacrolimus Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Tacrolimus Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• 20. Sirolimus
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Sirolimus Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Sirolimus Concentrations to Alter Doses
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Problems
• Answers to Problems
• VI. Other Drugs
• 21. Lithium
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Lithium Pharmacokinetics
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Lithium Serum Concentrations to Alter Dosages
• Dosing Strategies
• Problems
• Answers to Problems
• 22. Theophylline
• Introduction
• Therapeutic and Toxic Concentrations
• Clinical Monitoring Parameters
• Basic Clinical Pharmacokinetic Parameters
• Effects of Disease States and Conditions on Theophylline Pharmacokinetics and Dosing
• Drug Interactions
• Initial Dosage Determination Methods
• Use of Theophylline Serum Concentrations to Alter Doses
• Chiou Method
• Bayesian Pharmacokinetic Computer Programs
• Dosing Strategies
• Use of Theophylline Booster Doses to Immediately Increase Serum Concentrations
• Conversion of Theophylline Doses From Intravenous to Oral Route of Administration
• Removal of Theophylline Body Stores in Management of Theophylline Overdose
• Problems
• Answers to Problems
• Index

W tej ofercie kupujesz kod dostępowy umożliwiający dostęp do wskazanej treści. Kod umożliwia dostęp do treści za pomocą przeglądarki WWW, dedykowanej aplikacji iOS (Apple) ze sklepu App Store lub dedykowanej aplikacji Android ze sklepu Play. Kod oraz instrukcje otrzymasz pocztą elektroniczną niezwłocznie po zaksięgowaniu płatności. Brak możliwości pobrania pliku.

Na podstawie art. 38 pkt 13 Ustawy z dnia 30 maja 2014 roku o prawach konsumenta realizując kod dostępowy rezygnujesz z prawa do odstąpienia od umowy zawartej na odległość.

Typ licencji: licencja wieczysta.

BRAK MOŻLIWOŚCI POBRANIA PLIKU.

NIE PRZESYŁAMY PLIKÓW E-MAILEM.